Memorial Sloan Kettering opens outpatient surgery center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MEMORIAL SLOAN KETTERING CANCER CENTER opened its Josie Robertson Surgery Center. At full capacity, the outpatient center will accommodate 60 surgeries a day.

The facility’s 12 operating rooms are designed for procedures for breast cancer and reconstruction, as well as head and neck, gynecologic, and urologic cancers, including procedures that traditionally required inpatient admission. More than 50 percent of the 20,000 surgeries performed at MSK in 2015 were outpatient procedures.

“We are pioneering a new standard for outpatient surgery, one that seeks to transform cancer surgery worldwide,” said JRSC Director Brett Simon. “Our commitment to elevating the patient experience is reflected in our emphasis on minimizing the anxiety often felt by patients undergoing cancer surgery. Incorporating technology-based tools—including video conferencing that enables patients to speak with their families or doctors at remote locations and a real-time location system that allows patients to move freely through many parts of the building, both before and after procedures—can help reduce those feelings of anxiety and keep patients focused on the most important thing, their recovery.”

The 16-story, 179,000-square-foot building is located on Manhattan’s Upper East Side. It was established in part by a gift of $50 million from the Robertson Foundation, which was founded in 1996 by Josephine (Josie) Robertson and her husband, investor Julian Robertson, along with their family. Josie Robertson was elected to MSK’s Board of Overseers in 2004.

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login